focus -WSS

focus

author：knowledge 2025-09-30 00:47:09 - browse：9152

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： BIO to announce reorganization, senior leaders expected to depart

leisure time

WSS

Novel spinal cord stimulator treats paralysis without surgery

As health system earnings go up, health insurance stocks go down

Ask STAT: What do you want to know about ChatGPT in medicine?

Do masks work? RCTs can't tell us

The creative science of coining drug names

The science behind Janet Jackson's pregnancy at 49

Wikipedia

focus

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

As billionaires fund anti

Heart attack and stroke risk calculators need revising

Welsh Carson private equity firm escapes from FTC antitrust case

FDA approval of Sarepta Duchenne genetic therapy gives me hope

https://cbu01.alicdn.com/img/ibank/2017/027/816/4250618720_976529770.220x220xz.jpg

Bright Health sells Medicare Advantage business to Molina

AI for drug discovery: Experts on separating hype from reality

Medical records are filled with copy

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Wikipedia

Warren pushes Witty on UnitedHealth's control over physicians

Why we need to separate burnout from moral injury in health care

Weight bias in eating disorder treatment complicated by new weight loss drugs

Warren pushes Witty on UnitedHealth's control over physicians

Paxlovid study fails to answer questions over benefit for broader groups

The creative science of coining drug names

knowledge

hotspot

leisure time

hotspot